StockData
Teva Pharmaceutical Industries Ltd logo

Teva Pharmaceutical Industries Ltd

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$41.31−0.19 (-0.46%)

Close on Oct 19, 2026Market cap $48.13BP/E 68.9Yield –

Teva Pharmaceutical Industries Restructuring Expense Recognized in Operations by Quarter

Restructuring Expense Recognized in Operations — Total ($M)

Teva Pharmaceutical Industries Restructuring Expense Recognized in Operations: $58M in Q3 2026, up 100.0% from a year earlier.

Latest, Q3 2026
58
Period ended Sep 30, 2026
Change on a year earlier
+100.0%
29 in Q3 2025
History
43 quarters
Since Q1 2016
Sources
36
Documents cited below

Where the Q3 2026 figure comes from

Source: SEC Form 10-Q (0000818686-26-000006) ↗

Reported in SEC Form 10-K / Form 10-Q (XBRL & Footnotes).

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedRestructuring Expense Recognized in Operations — Total ($M)Year on yearSource
Q3 2026Sep 30, 202658+100.0%SEC Form 10-Q (0000818686-26-000006) ↗
Q2 2026Jun 30, 202638-75.3%SEC Form 10-Q (0001193125-26-323619) ↗
Q1 2026Mar 31, 202625+78.6%SEC Form 10-Q (0001193125-26-191513) ↗
Q4 2025Dec 31, 202529+31.8%SEC Form 10-K (0001193125-26-034532) ↗
Q3 2025Sep 30, 202529+38.1%SEC Form 10-Q (0000818686-26-000006) ↗
Q2 2025Jun 30, 2025154+755.6%SEC Form 10-Q (0001193125-26-323619) ↗
Q1 2025Mar 31, 202514+7.7%SEC Form 10-Q (0001193125-26-191513) ↗
Q4 2024Dec 31, 202422+22.2%SEC Form 10-K (0001193125-26-034532) ↗
Q3 2024Sep 30, 202421-22.2%SEC Form 10-Q (0001193125-25-266895) ↗
Q2 2024Jun 30, 202418+80.0%SEC Form 10-Q (0001193125-25-169296) ↗
Q1 2024Mar 31, 202413-76.8%SEC Form 10-Q (0001193125-25-114889) ↗
Q4 2023Dec 31, 202318-37.9%SEC Form 10-K (0001193125-26-034532) ↗
Q3 2023Sep 30, 202327+8.0%SEC Form 10-Q (0001193125-24-252039) ↗
Q2 2023Jun 30, 202310-71.4%SEC Form 10-Q (0001193125-24-189924) ↗
Q1 2023Mar 31, 202356-1.8%SEC Form 10-Q (0001193125-24-134200) ↗
Q4 2022Dec 31, 202229-21.6%SEC Form 10-K (0001193125-25-020826) ↗

Cite this data

StockData. (2026). Teva Pharmaceutical Industries Restructuring Expense Recognized in Operations ($M), quarterly Q1 2016–Q3 2026 [Data set]. Compiled from Teva Pharmaceutical Industries SEC filings and investor materials. https://stockdatahq.com/stocks/teva/kpis/restruct-exp-tot

See every metric in the Teva Pharmaceutical Industries KPI table. Data updated Nov 10, 2026.

See a number that looks wrong?